ArticleBMC ophthalmology2026
Real world outcomes of selective laser trabeculoplasty as primary treatment for glaucoma in Enugu Nigeria: a retrospective study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective Laser Trabeculoplasty (SLT) is a non-invasive procedure for managing open-angle glaucoma by reducing intraocular pressure (IOP). While effective as a primary treatment in various populations, data on its efficacy in sub-Saharan Africa, particularly Nigeria, are limited. This study evaluates SLT as a primary treatment for open-angle glaucoma in Enugu, Nigeria, addressing a regional gap in real-world outcomes.
methodsA retrospective chart review was conducted on 93 eyes of 50 patients who underwent SLT as primary treatment at The Eye Specialists Hospital, Enugu, Nigeria, between 2019 and 2021. Patients with open-angle glaucoma (primary, juvenile, or normal-tension) and a minimum 3-month follow-up were included. Kaplan Meier analysis was used to assess survival rates of SLT alone and SLT with additional treatment therapy overtime. Success was defined as an IOP reduction of ≥ 3 mmHg without additional intervention or ≥ 20% from baseline IOP. Data were analyzed using SPSS version 26, with statistical significance set at p < 0.05.
resultsMean baseline IOP was 17.0 ± 5.1 mmHg. Post-SLT, mean IOP decreased to 12.6 ± 3.3 mmHg (25% reduction) at 3 months, 12.3 ± 3.0 mmHg (25%) at 6 months, 11.9 ± 3.1 mmHg (25%) at 12 months, 12.3 ± 2.9 mmHg (22%) at 24 months, and 13.9 ± 3.3 mmHg (21%) at 36 months (all p < 0.05). Eyes with higher baseline IOP showed greater reductions up to 24 months. The number of antiglaucoma medications increased from 0 at baseline to 0.6 ± 1.0 at 12 months and 1.5 ± 0.9 at 36 months (p < 0.001). Success rates for SLT alone (without additional therapy) were 86% at 3 months, 83% at 6 months, 67% at 12 months, 54% at 24 months, and 43% at 36 months. Success rates for SLT with additional therapy were 87% at 3 months, 84% at 6 months, 80% at 12 months, and 64% at 36 months.
conclusionSLT is an effective primary treatment for reducing IOP in Nigerian patients with open-angle glaucoma, particularly those with higher baseline IOP, with minimal need for additional medications or surgery over 36 months. These findings support SLT’s role in resource-limited settings, though prospective studies are needed to confirm long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.